Ophthalmic Pharmaceutical Drugs

Summary

Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries. And increased healthcare spending in these countries is creating a strong demand for advanced ophthalmic therapeutic treatments. This in turn is leading to the rise in investments in ophthalmic drug research, and a parallel spurt in the commercial availability of innovative and promising ocular drugs. Ongoing research studies on developing pharmacologic IOP reducing drugs is expected to lead to the availability of powerful topical drugs with lesser side effects, and higher therapeutic efficacies, thereby overthrowing the present bottleneck of low patient compliance. Pharmacodiversity and newer classes of potent drugs together, are expected to encourage patient compliance, and improve patient outcomes. The market therefore is expected to get a much-awaited respite from the business, and economic repercussions of low patient compliance.

These and other market data and trends are presented in "Ophthalmic Pharmaceutical Drugs: A Global Market Perspective" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Contents

• 1.Methodology
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Quantitative Techniques & Reporting Level
• 2.Industry Overview
  • A Curtain Raiser
  • Drugs Developed in The Recent past
  • What The Future Holds in Store?
  • Where Does The Opportunity Lie?
  • in The Shifting Demographics...
  • Which Disease Segment Offers Abundant Opportunities for R&d Initiatives
  • Leading Companies & Their Areas of Research Interest/Focus
  • Business Opportunities in Ophthalmology: A Fact Sheet
  • Impediments in Picking The Ripe & Low Hanging Opportunities
  • Low Patient Compliance
  • What's The Antidote to Low Patient Compliance?
  • Innovation in Ophthalmic Pharmaceuticals: How Does IT Help Patients?
  • An Unequivocal Discussion about Ocular Drug Design and Delivery
  • Why Understanding of The Metabolic Activity of The Eye Is Important?
  • Pitfalls of Traditional Ocular Treatment
  • Ophthalmic Drug Delivery: A Recapitulation of Facts
  • Antidotes to Low Delivery of Ocular Drugs & High Side Effects
  • Prodrug
  • Soft Drugs (Sds)
  • Soft Corticosteroids
  • Drug Penetration Enhancers
  • Chitosan Based Drugs & Drug Delivery Systems
  • How Chitosan Is Used to Improve Ocular Drug Retention- on The Eye's Surface?
  • The Future of Ophthalmic Drug Delivery
  • A Straight Talk about Ophthalmic Drug Delivery Technologies
  • High Flying Expectations of Blistering Pace of Drug Development- Grounded
  • First Generation Advancements Made in Ocular Drugs
  • Second Generation Advancements Made in Ocular Drugs
  • Limiting Factors
• 3.Market Dynamics
  • Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty...
  • Ophthalmic Inserts Flaunt The Potential to Eclipse The Popularity of Eye Drops
  • Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs
  • Aging Population & Environmental Factors Drive Growth
  • Increase in Health Care Spending
  • Opportunities Abound in The Developing Countries
  • Innovative Products Lend Traction to Growth
  • Reimbursements: ""under The Umbrella""
• 4.Product Facts
• 5.Corporate Developments
  • Bausch & Lomb Acquires Iol Maker, Eyeonics
  • Akorn Inks Manufacture & Supply Agreement for Ophthalmic Solution
  • Crystalgenomics Enters into R&d Agreement with Bausch & Lomb
  • Genaera Corporation Quits Evizon Clinical Trials
  • Eyetech Inc Divests Anti-Platelet Derived Growth Factor (Pdgf) Aptamer- Program
  • Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs
  • Bausch & Lomb Acquire Soothe Products from Alimera
  • Froptix, Acuity, Exegenics Merge to Form Opko Corporation
  • Alimera, Emory Collaborate over Potential Ophthalmic Treatments Using Novel Antioxidants
  • Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix
  • Inspire Pharmaceuticals Rolls out Azasitefor Ocular Infections
  • Qlt Takes over Forsight Newco Ii, Inc
  • Inspire Pharmaceuticals Rolls out Azasitefor Ocular Infections
  • Novagali Obtains Fda Approval of Nova22007 Ind for Ph Iii Trial
  • Alimera Conducts Phase Iii Medidur Trial
  • Ista Pharmaceuticals Files Nda for XibromQd
  • Azasite Receives Fda Approval
• 6.Major Players
  • Akorn, Inc (USA)
  • Alcon Eye Care, Inc (USA)
  • Allergan, Inc. (USA)
  • Alimera Sciences, Inc (USA)
  • Bausch & Lomb, Inc (USA)
  • Genvec, Inc (USA)
  • Glaxosmithkline Plc (UK)
  • Inspire Pharmaceuticals, Inc (USA)
  • Ista Pharmaceuticals, Inc (USA)
  • Merck & Co., Inc (USA)
  • Opko Health, Inc (USA)
  • Otsuka Pharmaceutical Co., Ltd (Japan)
  • Pfizer Inc (USA)
  • Qlt, Inc. (Canada)
  • Santen Pharmaceutical Co. (Japan)
  • Santen Inc. (US)
• 7.Global Market Analytics
• 8.The United States
  • Emphasis on Greater Awareness about Ophthalmic Disorders
  • Growth Drivers in A Capsule
  • Impediments to Growth
  • Market Fact Sheet
  • Glaucoma Market: A Primer
  • Awareness among Patients
  • High Costs
  • Treatment Patterns Adopted by Doctors
  • The All Consuming Issue of Compliance
  • Market Share Statistics
  • The New Batting Order
  • Update on Drugs & Their Manufacturers in The US
  • Patent Expirations of Key Ophthalmic Product Brands in The United States
  • Statistical Findings on Ophthalmic Diseases in The United States
• 9.Canada
  • Lack of Awareness: A Key Issue
• 10.Japan
  • Growth Drivers
  • Market Data Statistics
• 11.Europe
  • A.France
  • B.Germany
  • C.The United Kingdom
  • D.Italy
  • E.Spain
  • F.Rest of Europe
• 12.Asia-Pacific
• 13.Latin America
• 14.Rest of World
  • Table 1: Prevalence of Glaucoma in The World -2006 (in 000 Individuals)
  • Table 2: Global Ophthalmic Pharmaceutical Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 3: Percentage Breakdown of Global Ophthalmic Pharmaceutical Drugs Market by Region for The Years 2008 &
  • Table 4: Global Glaucoma Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 5: Percentage Breakdown of Global Glaucoma Market by Region for The Years 2008 &
  • Table 6: Global Anti-Allergy Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 7: Percentage Breakdown of Global Anti-Allergy Market by Region for The Years 2008 &
  • Table 8: Global Anti-Infective Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 9: Percentage Breakdown of Global Anti-Infective Market by Region for The Years 2008 &
  • Table 10: Global Dry Eye Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 11: Percentage Breakdown of Global Dry Eye Market by Region for The Years 2008 &
  • Table 12: Global Anti-Inflammation Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 13: Percentage Breakdown of Global Anti-Inflammation Market by Region for The Years 2008 &
  • Table 14: Global Back of Eye Market by Region for The Period 2007-2015 (Sales in US$ Million)
  • Table 15: Percentage Breakdown of Global Back of Eye Market by Region for The Years 2008 &
  • Table 16: Global Other Treatment Category Market by Region for The Period 2007- 2015 (Sales in US$ Million)
  • Table 17: Percentage Breakdown of Global Other Treatment Category Market by Region for The Years 2008 &
  • Table 18: Market Shares of Leading Players in The US Market for Ophthalmic Pharmaceutical Drugs - 2007e
  • Table 19: Breakdown of Top 10 Eye/ Lens Care Brands in The US -
  • Table 20: Breakdown of Top 5 Eye Care Products in The US -
  • Table 21: Market Shares of Leading Players in The US Age-Related Wet Macular Degeneration Market
  • Table 22: Market Shares of Leading Players in The US Ocular Allergy Market -2007e
  • Table 23: Market Shares of Leading Players in The US Market for Ocular Nsaids (Topical Non-Steroidal Anti-Inflammatory Drugs) -
  • Table 24: Dollar Sales of Major Branded Drugs in The US Market for Age-Related Macular Degeneration - 2009 &
  • Table 25: Prevalence of Age-Related Wet Macular Degeneration in The US - 2009 &
  • Table 26: Number of Individuals Treated for Wet Amd in The US- 2009 &
  • Table 27: Prevalence of Ocular Hypertension (Oht) in The US- 2009 &
  • Table 28: Prevalence of Primary Open Angle Glaucoma (Poag) in The US - 2009 &
  • Table 29: Prevalence of Normal Tension Glaucoma (Ntg) in The US - 2009 &
  • Table 30: Prevalence of Exfoliative Glaucoma (Eg) in The United States for The Years 2009 & 2011 (in Thousand Individuals)
  • Table 31: Prevalence of Pigmentary Glaucoma (Pg) in The United States for The Years 2009 & 2011 (in Thousand Individuals)
  • Table 32 Breakdown of Number of Individuals Treated for Glaucoma by Type in The United Sates - 2009 and 2011 (in 000 Individuals)
  • Table 33: Prevalence of Ocular Allergy in The United States for The Years 2009 & 2012 (in Millions of Individuals)
  • Table 34: Number of Individuals Treated for Ocular Allergy in The United States - 2009 &
  • Table 35: Prevalence of Cataract in The US - 2009 &
  • Table 36: Number of Individuals Treated for Cataract with Ocular Nsaids (Topical Non-Steroidal Anti-Inflammatory Drugs) in The US - 2009 &
  • Table 37: Prevalence of Dry Eye in The US - 2009 &
  • Table 38: Number of Individuals Treated for Dry Eye in The US - 2009 &
  • Table 39: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in The US: 2007-2015 (Sales in US$ Million)
  • Table 40: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in The US for The Years 2008 &
  • Table 41: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Canada: 2007-2015 (Sales in US$ Million)
  • Table 42: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Canada for The Years 2008 &
  • Table 43: Percentage Breakdown of Japanese Market for Prescription Ophthalmic Drugs by Therapeutic Area -
  • Table 44: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Japan: 2007-2015 (Sales in US$ Million)
  • Table 45: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Japan for The Years 2008 &
  • Table 46: Ophthalmic Pharmaceutical Drugs Market by Region in Europe: 2007-2015 (Sales in US$ Million)
  • Table 47: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Region in Europe for The Years 2008 &
  • Table 48: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Europe: 2007-2015 (Sales in US$ Million)
  • Table 49: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Europe for The Years 2008 &
  • Table 50: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in France: 2007-2015 (Sales in US$ Million)
  • Table 51: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in France for The Years 2008 &
  • Table 52: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Germany: 2007-2015 (Sales in US$ Million)
  • Table 53: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Germany for The Years 2008 &
  • Table 54: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in The UK: 2007-2015 (Sales in US$ Million)
  • Table 55: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in The UK for The Years 2008 &
  • Table 56: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Italy: 2007-2015 (Sales in US$ Million)
  • Table 57: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Italy for The Years 2008 &
  • Table 58: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Spain: 2007-2015 (Sales in US$ Million)
  • Table 59: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Spain for The Years 2008 &
  • Table 60: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of Europe: 2007-2015 (Sales in US$ Million)
  • Table 61: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of Europe for The Years 2008 &
  • Table 62: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Asia-Pacific: 2007-2015 (Sales in US$ Million)
  • Table 63: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Asia-Pacific for The Years 2008 &
  • Table 64: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Latin America: 2007-2015 (Sales in US$ Million)
  • Table 65: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Latin America for The Years 2008 &
  • Table 66: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of World: 2007-2015 (Sales in US$ Million)
  • Table 67: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of World for The Years 2008 &
• Companies Profiled